ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "IL-6"

  • Abstract Number: 1208 • ACR Convergence 2021

    Composite Articular Index Including Acute Phase Reactants Should Not Be Used in Patients with Rheumatoid Arthritis Treated with Il6 Inhibitors but May Be Useful in Those Receiving Jak Inhibitors: Ultrasound Evidence

    Andrés Ponce1, Beatriz Frade-Sosa2, Ramirez Julio3, Núria Sapena1, Roberto Gumucio2, Virginia Ruiz-Esquide2, Rosa Morlà2, Marta Bassas2, Juan D Cañete4 and Jose A Gomez-Puerta2, 1Rheumatology Department, Hospital Clínic, Barcelona, Spain, 2Hospital Clínic de Barcelona, Barcelona, Spain, 3Hospital Universitari Clinic, Barcelona, Spain, 4Rheumatology Department, Hospital Clinic, Barcelona, Spain

    Background/Purpose: IL6 inhibitors (IL6i) have a dramatic effect on the reduction of C reactive protein (CRP) that does not always correlate with a significant improvement…
  • Abstract Number: 1 • 2019 ACR/ARP Annual Meeting

    Interleukin-6 Promotes Osteoclast-like Phenotype in Human Rheumatoid Arthritis Synovial Fibroblasts

    Anil Singh1, Mahamudul Haque 1, Bhanupriya Madarampalli 2 and Salahuddin Ahmed 3, 1Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA, Spokane, WA, 2University of Washington, Seattle, WA, 3Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA. Division of Rheumatology, University of Washington School of Medicine, Seattle, WA, Spokane, WA

    Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disorder characterized by chronic inflammation and joint destruction caused by pro-inflammatory cytokines. Progressive joint damage is also an…
  • Abstract Number: 1387 • 2019 ACR/ARP Annual Meeting

    Low Probability of Clinical Worsening Following Switching Biologic DMARD in Patients with RA and Partial Response to Adalimumab

    Jeffrey Curtis1, Daniel Aletaha 2, Gerd Burmester 3, Kerri Ford 4, Hubert van Hoogstraten 5, Henry Leher 6, Karthinathan Thangavelu 7 and Vivian Bykerk 8, 1University of Alabama at Birmingham, Birmingham, AL, 2Medical University of Vienna, Vienna, Austria, 3Charité—University Medicine Berlin, Berlin, Germany, 4Sanofi Genzyme, Bridgewater, NJ, 5Sanofi, Bridgewater, NJ, 6Regeneron Pharmaceuticals, Inc, Tarrytown, NY, 7Sanofi Genzyme, Boston, MA, 8Hospital for Special Surgery, New York City, NY

    Background/Purpose: Guidelines recommend adjusting therapy in patients with RA who fail to reach low disease activity or remission. Partial responders to a TNF inhibitor may…
  • Abstract Number: 1393 • 2019 ACR/ARP Annual Meeting

    Impact of Sarilumab on Unacceptable Pain and Inflammation Control in Moderately-to-Severely Active Rheumatoid Arthritis (RA) Patients in 3 Phase 3 Studies

    Vivian Bykerk1, Wenhui Wei 2, Susan Boklage 2, Toshio Kimura 2, Stefano Fiore 3 and Gregory St John 4, 1Hospital for Special Surgery, New York City, NY, 2Regeneron Pharmaceuticals, Inc, Tarrytown, NY, 3Sanofi Genzyme, Bridgewater, NJ, 4Regeneron Pharmaceuticals, Inc., Tarrytown, NY

    Background/Purpose: Pain, a core-set domain and a troubling symptom to patients with RA, may be directly related to inflammation. Unacceptable pain (UP) levels may persist…
  • Abstract Number: 1707 • 2019 ACR/ARP Annual Meeting

    IL-6 Promotes IgG4-related Disease by Inducing Fibroblast-dependent Tfh Cell and B Cell Differentiation Factors

    Zongfei Ji1, Rongyi Chen 2, Xiaomeng Cui 2, Lili Ma 2, Xiufang Kong 3, Lingying Ma 2, Ying Sun 2, Xiaomin Dai 2, Zhuojun Zhang 2, Huiyong Chen 2 and Lindi Jiang 2, 1Department of Rheumatology, Zhongshan hospital, Fudan University, Shanghai, China (People's Republic), 2Zhongshan hospital, Fudan University, Shanghai, China (People's Republic), 3University of Michigan & Fudan University, Ann Arbor, MI

    Background/Purpose: Considering the unsatisfied effect of conventional therapy, to investigate the pathogenesis of IgG4-related disease (IgG4-RD) is crucial to explore novel treatment strategies.  This study…
  • Abstract Number: 1976 • 2019 ACR/ARP Annual Meeting

    Regulation of Interleukin-1β (IL-1β)-induced COX-2 Expression and IL-6 and MMP-1 Production in Human OA Synovial Fibroblasts by Guanylate Binding Protein 5

    Mahamudul Haque1, Madeline McDougal 1, Anil Singh 1 and Salahuddin Ahmed 2, 1Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA, SPOKANE, WA, 2Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA. Division of Rheumatology, University of Washington School of Medicine, Seattle, WA, Spokane, WA

    Background/Purpose: Osteoarthritis (OA) is a chronic degenerative joint disease caused by synovial inflammation and cartilage degradation primarily driven by interleukin-1beta (IL-1β). Studies suggest that TNF-stimulated…
  • Abstract Number: 2351 • 2019 ACR/ARP Annual Meeting

    Withdrawal of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Sarilumab Open-Label EXTEND Study: Efficacy and Safety Analysis

    Jeffrey Curtis1, Yong Lin 2, Karthinathan Thangavelu 3, Marina Stanislav 4, Gregory St John 5, Antonio Gómez-Centeno 6, Carlo Selmi 7, Thomas Huizinga 8, José Antonio Maldonado-Cocco 9, Marwan Bukhari 10 and Frank Buttgereit 11, 1University of Alabama at Birmingham, Birmingham, AL, 2Sanofi, Bridgewater, NJ, 3Sanofi Genzyme, Boston, MA, 4V.A. Nasonova Research Rheumatology Institute, Moscow, Russia, 5Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 6Corporació Sanitària Parc Taulí, Barcelona, Spain, 7Humanitas Research Hospital, University of Milan, Milan, Italy, 8Leiden University Medical Center, Leiden, Netherlands, 9Buenos Aires University School of Medicine, Buenos Aires, Argentina, 10Lancaster University Medical School, Lancaster, United Kingdom, 11Charité-Universitätsmedizin Berlin, Berlin, Germany

    Background/Purpose: The EXTEND open-label extension study (NCT01146652) is collecting data on long-term treatment of RA with sarilumab as monotherapy and in combination with conventional synthetic…
  • Abstract Number: 2392 • 2019 ACR/ARP Annual Meeting

    The Effectiveness of anti-IL-6 Therapy to Elderly-onset Rheumatoid Arthritis

    Takayasu Ando1, Takeshi Suzuki 2, Yutaka Gotou 1 and Kimito Kawahata 3, 1Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan, 2Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, 3Rheumatology and Allergology, St. Marianna University School of Medicine, Tokyo, Japan

    Background/Purpose:  In daily practice, our rheumatologist has experienced different clinical feature of elderly-onset rheumatoid arthritis (EORA) compared with younger-onset RA (YORA). In EORA patients, serological…
  • Abstract Number: 2493 • 2019 ACR/ARP Annual Meeting

    IL-6 and TNF-α Influence on Clinical Manifestations, Activity and Comorbidity in Psoriatic Arthritis Patients

    Maria Elisa Acosta1, Luis Gomez-Lechon 1, Guadalupe Manzano Canabal 1, Olga Compan 2, Cristina Hidalgo 3, Olga Martinez 1, Ana Turrión 1, Javier del Pino 1 and Carlos Montilla 1, 1Hospital Clínico Universitario de Salamanca, Salamanca, Spain, 2Hospital Clinico Universitario de Salamanca, SALAMANCA, Spain, 3Hospital Clínico Universitario de Salamanca, Salamanca, Castilla y Leon, Spain

    Background/Purpose: The activation of the Th-1 and Th-17 lymphocytes response seems to be one of the causes associated with PsA onset. During this process cytokines…
  • Abstract Number: 2494 • 2019 ACR/ARP Annual Meeting

    Comparison of Comorbidity in Spondyloarthritis: Influence on Inflammatory Activity in Patients with Psoriatic Arthritis

    Luis Gomez-Lechon1, Maria Elisa Acosta 1, Guadalupe Manzano Canabal 1, Olga Compan 1, Cristina Hidalgo 2, Olga Martinez 1, Ana Turrión 1, Javier del Pino 1 and Carlos Montilla 1, 1Hospital Clínico Universitario de Salamanca, Salamanca, Spain, 2Hospital Clínico Universitario de Salamanca, Salamanca, Castilla y Leon, Spain

    Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous disease that is included in the group of spondyloarthritis. Although PsA has its own clinical characteristics, it has…
  • Abstract Number: L08 • 2018 ACR/ARHP Annual Meeting

    High Baseline Serum IL-6 Identifies a Subgroup of Rheumatoid Arthritis Patients with Rapid Joint Damage and Clinical Progression and Predicts Increased Sarilumab Treatment Response

    Anita Boyapati1, Jérôme Msihid2, Sergio Schwartzman3, Ernest Choy4, Mark C. Genovese5, Gerd R. Burmester6, Gordon Lam7, Toshio Kimura1, Jonathan Sadeh8 and Neil M.H. Graham1, 1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 2Sanofi Chilly-Mazarin, Chilly-Mazarin, NJ, France, 3Hospital for Special Surgery, New York, NY, 4CREATE Center, Cardiff University School of Medicine, Cardiff, Great Britain, 5Division of Immunology & Rheumatology, Stanford University, Stanford, CA, 6Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany, 7Atrium Health, Charlotte, NC, 8Sanofi, Bridgewater, NJ

    Background/Purpose: Clinical application of biomarkers to predict response to therapy is the next frontier in RA.  Despite the key role of IL-6 in RA, the…
  • Abstract Number: 1052 • 2018 ACR/ARHP Annual Meeting

    Detection of Precursors of RANK- Osteoclast-like Cells (Olcs) in Peripheral Blood and Olcs in Bone Tissue from Rheumatoid Arthritis Patients

    Kazuhiro Yokota1, Shinya Tanaka2, Miyoko Sekikawa2, Yoshimi Aizaki1, Kojiro Sato1, Hiromi Oda2 and Toshihide Mimura1, 1Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, 2Department of Orthopaedic Surgery, Saitama Medical University, Saitama, Japan

    Background/Purpose: Proinflammatory cytokines play an important role in bone destruction in rheumatoid arthritis (RA), as inferred by the efficacy of biologics. Previously, we reported that…
  • Abstract Number: 1053 • 2018 ACR/ARHP Annual Meeting

    Synovial Inflammation Identifies Patients Clusters in Osteoarthritis

    Hannah Labinsky1, Paul Panipinto1, Kaytlyn Ly2, Deric Khuat2, Bhanupriya Madarampalli3, Vineet Mahajan1, Jonathan Clabeaux4, Kevin MacDonald4, Peter Verdin4, Jane H. Buckner2 and Erika H. Noss3, 1Medicine, Division of Rheumatology, University of Washington, Seattle, WA, 2Benaroya Research Institute at Virginia Mason, Seattle, WA, 3Rheumatology, University of Washington, Seattle, WA, 4Orthopedics, Virginia Mason Hospital, Seattle, WA

    Background/Purpose: Synovial membrane inflammation is common in osteoarthritis (OA). Inflammation may be present at all disease stages, increases the risk of cartilage injury, and is…
  • Abstract Number: 1511 • 2018 ACR/ARHP Annual Meeting

    The Relationship between Lipid Profile Changes and Inflammation across the Phase 3 Sarilumab Rheumatoid Arthritis (RA) Developmental Program

    Christina Charles-Schoeman1, Gregory St. John2, Henry Leher2, Toshio Kimura2, Hubert van Hoogstraten3, Michael T. Nurmohamed4, Miguel Angel González-Gay5 and Edward C. Keystone6, 1Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, 2Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 3Sanofi Genzyme, Bridgewater, NJ, 4VU University Medical Center, Amsterdam, Netherlands, 5University Hospital Marques de Valdecilla, Santander, Spain, 6University of Toronto and Mount Sinai Hospital, Toronto, ON, Canada

    Background/Purpose: Sarilumab showed superiority to placebo and adalimumab in Phase 3 trials. Serum lipids may be reduced in the setting of chronic inflammation associated with…
  • Abstract Number: 1521 • 2018 ACR/ARHP Annual Meeting

    Anti-IL-6 Therapy Modulates Leptin in Patients with Rheumatoid Arthritis

    Sara Remuzgo-Martínez1, Fernanda Genre1, Verónica Pulito-Cueto1, Verónica Mijares1, Leticia Lera-Gómez1, Jaime Calvo-Alén2, Ricardo Blanco1, Oreste Gualillo3, Javier Llorca4, Santos Castañeda5, Raquel Lopez-Mejías1 and Miguel Angel González-Gay1,6,7, 1Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, Santander, Spain, 2Rheumatology Department, Hospital Universitario Araba. Vitoria-Gasteiz, Alava, Spain, 3SERGAS (Servizo Galego de Saude) and IDIS (Instituto de Investigación Sanitaria de Santiago), The NEIRID Group (Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases), Santiago University Clinical Hospital, Santiago de Compostela, Spain, Santiago de Compostela, Spain, 4Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, Santander, Spain, 5Hospital Universitario La Princesa, IIS-Princesa, Madrid, Spain, 6Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 7School of Medicine, University of Cantabria, Santander, Spain, Santander, Spain

    Background/Purpose: Leptin is an adipokine that plays an important role in the regulation of body weight and also participates in immune homeostasis and inflammatory processes1,2.…
  • 1
  • 2
  • 3
  • …
  • 9
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology